Viral Vector and Plasmid DNA Manufacturing Market Report & Growth Analysis 2027
[Research Report] The viral vector and plasmid DNA manufacturing market size was projected to grow from US$ 459.4 million in 2019 to US$ 2,247.7 million by 2027; it is further estimated to record a CAGR of 22.1% from 2020–2027.
Analyst Perspective:
The increasing demand for gene therapy and advancement in gene editing technologies for the development of treatment option for various chronic disorders, viral infection, and others are driving the viral vector and plasmid DNA manufacturing market growth. Additionally, increase in research activities and growing investments in pharmaceutical & biotechnology industries followed by the favorable regulatory scenario is expected to anticipate the market growth. Moreover, integration of advanced computing technologies is further expected to enhance the application area of viral vector and plasmid DNA manufacturing in near future which in turn propelling the market growth.
Market Overview:
A viral vector is a tool used in gene delivery and manipulation. It is modified virus that has been engineered to carry and deliver specific genes into cells. Viral vectors are commonly used in gene therapy for gene editing application, as they can efficiently deliver genetic material into target cells. Plasmid vector is a small circular piece of DNA that is separate from the chromosomal DNA in a cell. Plasmids can replicate independently and are commonly found in bacteria. In research, plasmids are often used as vectors to introduce genes into cells for various purposes, such as protein production or genetic engineering. Both viral vector and plasmid DNA are essential tools for gene delivery and manipulation in research, allowing researchers to understand potential applications.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Viral Vector and Plasmid DNA Manufacturing Market: Strategic Insights
Market Size Value in US$ 459.4 million in 2019 Market Size Value by US$ 2,247.7 million by 2027 Growth rate CAGR of 22.1% from 2020 to 2027 Forecast Period 2020-2027 Base Year 2019
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Viral Vector and Plasmid DNA Manufacturing Market: Strategic Insights
| Market Size Value in | US$ 459.4 million in 2019 |
| Market Size Value by | US$ 2,247.7 million by 2027 |
| Growth rate | CAGR of 22.1% from 2020 to 2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2019 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Market Trends:
I
ntegration of Advanced Computing Technologies
Emergence of revolutionary technologies such as artificial intelligence, data science, natural language processing, and others are estimated to reshape the future of healthcare technologies during the forecast period. However, gene therapy offers innovative solutions for treatment of diseases, the execution of it faces some technical challenges. For instance, error in gene replacing may lead to harmful mutations in the DNA, resulting into severe health problems. To achieve high level of precision in procedures, intelligent algorithms can offer a significant way. Further, a majority of players are engaged in R&D of new technologies, which will deal with increasing demand for modern technologies. For instance, in March 2019, Oxford Biomedica entered into strategic collaboration with Microsoft to improve gene therapies. Moreover, in May 2020, Dyno Therapeutics announced its proposed financial investments of an estimated US$ 2.0 billion to design AI-based gene therapies. Such events represent a huge opportunity for the integrations of advanced computing technologies, which will eventually redefine the concept of gene therapies during years to come.
Segmental Analysis:
Based on application, the viral vector and plasmid DNA manufacturing market is segmented into cancer, inherited disorders, viral infections, and others. The cancer segment held the largest share of the market in 2019, and the same segment is anticipated to register the highest CAGR of 22.6% during the forecast period. Viral vectors and non-viral vectors have their application and are being studied for both preventive and therapeutic applications in cancer or oncology. Viral vector-based immunization with anticancer agents or delivery of anticancer genes is some critical areas of research that have shown steady progress. Moreover, the government approvals of lentiviral vector-based CAR-T cell therapies, which is used for the treatment of Acute Lymphoblastic Leukemia (ALL) and large B cell lymphoma, have attracted considerable attention from users. Viral vectors and non-viral vectors have resulted in a significant proliferation of the cancer-based pipeline projects on advanced therapies. For instance, around two-thirds of the research in gene therapy is focused on oncology. The above-mentioned factors have contributed to the dominance of cancer over other disease areas. Based on products, the global viral vector and plasmid DNA manufacturing market is bifurcated into viral and non-viral vectors. In 2019, the viral vectors segment held the largest market share, and the same segment is expected to grow at the fastest CAGR during the coming years.
Regional Analysis:
Based on geography, global viral vector and plasmid DNA manufacturing market is segmented into North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America. North America held the largest viral vector and plasmid DNA manufacturing market share which is closely followed by Europe. The US held the largest share of the North American viral vector and plasmid DNA manufacturing market in 2019. The growth of the US market is primarily driven by the growing awareness regarding benefits of gene therapy, increasing research and development activities, and rising demand for advanced therapeutic solutions to treat chronic conditions and viral infections.
In addition, increasing demand for viral vectors due to growing adoption of gene therapies is also anticipated to drive the US viral vector and plasmid DNA manufacturing market growth during the forecast period. In addition, due to this growing demand, major players in the market are focusing on expansion of their viral vector manufacturing capacity. For instance, in May 2020, Thermo Fisher Scientific Inc. announced its plan to expand viral vector manufacturing capacity. According to company estimates, the new facility will be operational by 2022. Further, in April 2020, Merck announced its proposed plan to open a new US-based manufacturing facility for viral vectors. The company has invested around US$ 112.6 million for this proposed expansion.
In Canada, the viral vector and plasmid DNA manufacturing market growth is expected owing to the development of the healthcare systems and rapidly increasing adoption of modern cell related technologies. On the other hand, in Mexico, it is expected that the viral vector and plasmid DNA manufacturing market is likely to experience growth opportunities due increasing awareness of benefits offered by viral vectors and plasmid DNA.
Key Player Analysis:
The viral vector and plasmid DNA manufacturing market majorly consists of the players such as Brammer Bio, Sanofi, Cardinal Health Inc, FUJIFILM Diosynth Biotechnologies, Cell and Gene Therapy Catapult, Cobra Biologics, FinVector, Kaneka Eurogentec SA, MassBiologics, Spark Therapeutics, and Uniqure among others. Among the players in the viral vector and plasmid DNA manufacturing market, Sanofi and FUJIFILM Diosynth Biotechnologies are the top two players owing to their organic and inorganic activities.
Viral Vector and Plasmid DNA Manufacturing Market Report Scope
Recent Developments:
Inorganic and organic strategies such as mergers and acquisitions are highly adopted by companies in the viral vector and plasmid DNA manufacturing market. A few recent key market developments are listed below:
- In March 2023, Sartorius acquired French company Polyplus for 2.4 billion euros ($2.6 billion). The deal gives Sartorius additional know-how in nucleic acid delivery, including transfection reagents and plasmid DNA design, all of which are key elements in the production of viral vectors for building cell and gene therapies.
- In July 2021, Thermo Fisher Scientific Inc. opened a new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif., enabling it to meet rapidly growing demand for plasmid DNA-based therapies and vital mRNA-based vaccines.
- In March 2021, WACKER acquired 100% of the shares in pharmaceutical contract manufacturer Genopis Inc. from Helixmith Co Ltd, Seoul (South Korea) and Medivate Partners LLC, Seoul (South Korea) in February. The signing of the related agreement was followed by the successful closing in late February and, now, the acquisition’s new name: Wacker Biotech US Inc.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product, and Application
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
Gene delivery into target cells can be performed using several different vectors. These are broadly classified into viral and non-viral vectors, both of which present benefits and risks. Viral vectors are tools that are commonly used by molecular biologists to deliver genetic material into cells. The non-viral vectors are Naked DNA, particle-based, and chemical-based.
The viral vector & plasmid DNA manufacturing market majorly consists of the players such as Brammer Bio, Sanofi, Cardinal Health Inc., FUJIFILM Diosynth Biotechnologies. Cell and Gene Therapy Catapult, Cobra Biologics, FinVector, Kaneka Eurogentec S.A., MassBiologics, Spark Therapeutics, and Uniqure among others.
Driving factor such as growing awareness of gene therapy and increasing prevalence of genetic disorders and infectious diseases across the world are expected to upsurge the market growth. In addition, growth in the global healthcare market is likely to have a positive impact on the market in the coming years.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Viral Vector and Plasmid DNA Manufacturing Market – By Product
1.3.2 Global Viral Vector and Plasmid DNA Manufacturing Market – By Application
1.3.3 Global Viral Vector and Plasmid DNA Manufacturing Market – By Geography
2. Viral Vector and Plasmid DNA Manufacturing Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Viral Vector and Plasmid DNA Manufacturing – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.2.2 Europe – PEST Analysis
4.2.3 Asia Pacific – PEST Analysis
4.2.4 Middle East and Africa (MEA) – PEST Analysis
4.2.5 South and Central America (SCAM) – PEST Analysis
4.3 Expert Opinion
5. Viral Vector and Plasmid DNA Manufacturing Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Growing Awareness of Gene Therapy
5.1.2 Increasing Prevalence of Genetic Disorders and Infectious Diseases
5.2 Market Restraints
5.2.1 High Cost Associated with Gene Therapies
5.3 Market Opportunities
5.3.1 Increasing Funding for Gene Therapies
5.4 Future Trends
5.4.1 Integration of Advanced Computing Technologies
5.5 Impact Analysis
6. Viral Vector and Plasmid DNA Manufacturing Market – Global Analysis
6.1 Global Viral Vector and Plasmid DNA Manufacturing Market Revenue Forecast And Analysis
6.2 Global Viral Vector and Plasmid DNA Manufacturing Market, By Geography - Forecast And Analysis
6.3 Market Positioning of Key Players
7. Viral Vector and Plasmid DNA Manufacturing Market– By Product
7.1 Overview
7.2 Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)
7.3 Viral Vectors
7.3.1 Overview
7.3.2 Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
7.4 Non-Viral Vectors
7.4.1 Overview
7.4.2 Non-Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
8. Viral Vector and Plasmid DNA Manufacturing Market Analysis By Application
8.1 Overview
8.2 Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)
8.3 Cancer
8.3.1 Overview
8.3.2 Cancer: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Inherited Disorders
8.4.1 Overview
8.4.2 Inherited Disorders: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Viral Infections
8.5.1 Overview
8.5.2 Viral-Infections: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
9. Viral Vector and Plasmid DNA Manufacturing Market – Geographic Analysis
9.1 North America: Viral Vector and Plasmid DNA Manufacturing Market
9.1.1 Overview
9.1.2 North America: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.1.3 North America: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.1.4 North America: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.1.5 North America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)
9.1.6 US: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.1.6.1 US: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.1.6.2 US: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.1.6.3 US: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.1.7 Canada: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.1.7.1 Canada: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.1.7.2 Canada: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.1.7.3 Canada: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.1.8 Mexico: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.1.8.1 Mexico: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.1.8.2 Mexico: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.1.8.3 Mexico: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.2 Europe: Viral Vector and Plasmid DNA Manufacturing Market
9.2.1 Overview
9.2.2 Europe: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.2.3 Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.2.4 Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.2.5 Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)
9.2.6 Germany: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.6.1 Germany: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.6.2 Germany: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.2.6.3 Germany: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.2.7 UK: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.7.1 UK: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.7.2 United Kingdom: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.2.7.3 United Kingdom: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.2.8 France: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.8.1 France: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.8.2 France: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.2.8.3 France: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.2.9 Spain: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.9.1 Spain: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.9.2 Spain: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.2.9.3 Spain: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.2.10 Italy: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.10.1 Italy: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.2.10.2 Italy: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.2.10.3 Italy: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.3 Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market
9.3.1 Overview
9.3.2 Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.3.3 Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.3.4 Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.3.5 Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)
9.3.6 China: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.6.1 China: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.6.2 China: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.3.6.3 China: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.3.7 Japan: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.7.1 Japan: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.7.2 Japan: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.3.7.3 Japan: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.3.8 India: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.8.1 India: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.8.2 India: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.3.8.3 India: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.3.9 South Korea: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.9.1 South Korea: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.9.2 South Korea: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.3.9.3 South Korea: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.3.10 Australia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.10.1 Australia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.3.10.2 Australia: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.3.10.3 Australia: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.4 Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market
9.4.1 Overview
9.4.2 Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (USD Million)
9.4.3 Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.4.4 Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.4.5 Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market Share by Country – 2019 & 2027, (%)
9.4.6 Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.4.6.1 Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.4.6.2 Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.4.6.3 Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.4.7 UAE: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.4.7.1 UAE: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.4.7.2 UAE: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.4.7.3 UAE: Viral Vector and Plasmid DNA Manufacturing Market, by Action Mechanism, 2018–2027 (USD Million)
9.4.8 South Africa: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
9.4.8.1 South Africa: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.4.8.2 South Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.4.8.3 South Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.5 South and Central America: Viral Vector and Plasmid DNA Manufacturing Market
9.5.1 Overview
9.5.2 South and Central America: Viral Vector and Plasmid DNA Manufacturing Market - Revenue and Forecast to 2027 (US$ Million)
9.5.3 South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.5.4 South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.5.5 South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019 & 2027 (%)
9.5.6 Brazil: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.5.6.1 Brazil: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.5.6.2 Brazil: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.5.6.3 Brazil: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
9.5.7 Argentina: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.5.7.1 Argentina: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
9.5.7.2 Argentina: Viral Vector and Plasmid DNA Manufacturing Market, by Product, 2018–2027 (USD Million)
9.5.7.3 Argentina: Viral Vector and Plasmid DNA Manufacturing Market, by Application, 2018–2027 (USD Million)
10. Impact of COVID-19 Pandemic on Global Viral Vector and Plasmid DNA Manufacturing Market
10.1 North America: Impact assessment of COVID-19 Pandemic
10.2 Europe: Impact Assessment of COVID-19 Pandemic
10.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
10.4 Rest of the World: Impact Assessment of COVID-19 Pandemic
11. Viral Vector and Plasma DNA Manufacturing Market – Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 Sanofi
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 FUJIFILM Diosynth Biotechnologies
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 BRAMMER BIO (Thermo Fisher Scientific Inc.)
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Cell and Gene Therapy Catapult
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Cobra Biologics
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 FinVector
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Kaneka Eurogentec S.A.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 MassBiologics
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Spark Therapeutics, Inc.
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 UniQure N.V.
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 2. North America Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 3. US Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 4. US Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 5. Canada Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 6. Canada Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 7. Mexico Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 8. Mexico Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 9. Europe Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 10. Europe Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 11. Germany Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 12. Germany Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 13. United Kingdom Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 14. United Kingdom Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 15. France Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 16. France Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 17. Spain Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 18. Spain Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 19. Italy Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 20. Italy Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 21. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 22. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 23. China Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 24. China Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 25. Japan Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 26. Japan Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 27. India Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 28. India Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 29. South Korea Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 30. South Korea Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 31. Australia Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 32. Australia Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 33. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)
Table 34. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 35. Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)
Table 36. Saudi Arabia Viral Vector and Plasmid DNA Manufacturing Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 37. UAE Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)
Table 38. UAE Viral Vector and Plasmid DNA Manufacturing Market, by Action Mechanism – Revenue and Forecast to 2027 (USD Million)
Table 39. South Africa Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)
Table 40. South Africa Viral Vector and Plasmid DNA Manufacturing Market, by Application– Revenue and Forecast to 2027 (USD Million)
Table 41. South and Central America Viral Vector and Plasmid DNA Manufacturing Market, by Product– Revenue and Forecast to 2027 (USD Million)
Table 42. South and Central America Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 43. Brazil Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 44. Brazil Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 45. Argentina Viral Vector and Plasmid DNA Manufacturing Market, by Product – Revenue and Forecast to 2027 (USD Million)
Table 46. Argentina Viral Vector and Plasmid DNA Manufacturing Market, by Application – Revenue and Forecast to 2027 (USD Million)
Table 47. Organic Developments Done By Companies
Table 48. Inorganic Developments Done By Companies
Table 49. Glossary of Terms, Viral Vector and Plasmid DNA Manufacturing Market
LIST OF FIGURES
Figure 1. Viral Vector and Plasmid DNA Manufacturing Market Segmentation
Figure 2. Viral Vector and Plasmid DNA Manufacturing Segmentation, By Region
Figure 3. Global Viral Vector and Plasmid DNA Manufacturing Market Overview
Figure 4. Viral Vectors Segment Held Largest Share of Viral Vector and Plasmid DNA Manufacturing Market
Figure 5. APAC to Show Significant Growth During Forecast Period
Figure 6. Viral Vector and Plasmid DNA Manufacturing Market, by Geography (US$ Million)
Figure 7. Global Viral Vector and Plasmid DNA Manufacturing Market – Leading Country Markets (US$ Million)
Figure 8. Global Viral Vector and Plasmid DNA Manufacturing Market, Industry Landscape
Figure 9. North America PEST Analysis
Figure 10. Europe PEST Analysis
Figure 11. Asia Pacific PEST Analysis
Figure 12. Middle East & Africa PEST Analysis
Figure 13. South and Central America (SCAM) PEST Analysis
Figure 14. Viral Vector and Plasmid DNA Manufacturing Market Impact Analysis of Drivers and Restraints
Figure 15. Global Viral Vector and Plasmid DNA Manufacturing Market – Revenue Forecast And Analysis – 2019- 2027
Figure 16. Global Viral Vector and Plasmid DNA Manufacturing Market – By Geography Forecast And Analysis – 2019- 2027
Figure 17. Market Positioning Of Key Players In Global Viral Vector and Plasmid DNA Manufacturing Market
Figure 18. Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)
Figure 19. Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
Figure 20. Non-Viral Vectors: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
Figure 21. Viral Vector and Plasmid DNA Manufacturing Market Revenue Share, by Product (2019 and 2027)
Figure 22. Cancer: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
Figure 23. Inherited Disorders: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
Figure 24. Viral-Infections: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
Figure 25. Others: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
Figure 26. North America: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)
Figure 27. North America Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)
Figure 28. North America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019 & 2027 (%)
Figure 29. US: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 30. Canada: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 31. Mexico: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 32. Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)
Figure 33. Europe Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)
Figure 34. Europe: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019& 2027 (%)
Figure 35. Germany: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 36. UK: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 37. France: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 38. Spain: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 39. Italy: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 40. Asia Pacific: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)
Figure 41. Asia Pacific Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)
Figure 42. China: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 43. Japan: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 44. India: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 45. South Korea: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 46. Australia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 47. Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)
Figure 48. Middle East & Africa Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)
Figure 49. Middle East & Africa: Viral Vector and Plasmid DNA Manufacturing Market Share by Country – 2019 & 2027, (%)
Figure 50. Saudi Arabia: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 51. UAE: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (US$ Million)
Figure 52. South Africa: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 53. South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Key Country – Revenue (2019) (USD Million)
Figure 54. South and Central America Viral Vector and Plasmid DNA Manufacturing Market Revenue and Forecast to 2027 (USD Million)
Figure 55. South and Central America: Viral Vector and Plasmid DNA Manufacturing Market, by Country, 2019 & 2027 (%)
Figure 56. Brazil: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 57. Argentina: Viral Vector and Plasmid DNA Manufacturing Market – Revenue and Forecast to 2027 (USD Million)
Figure 58. Impact Of COVID-19 Pandemic in North American Country Markets
Figure 59. Impact Of COVID-19 Pandemic in European Country Markets
Figure 60. Impact Of COVID-19 Pandemic in Asia Pacifican Country Markets
Figure 61. Impact Of COVID-19 Pandemic in Rest of the World Countries Market
Figure 62. Growth Strategies Done by the Companies in the Market, (%)
The List of Companies - Portable and Wearable Dialysis Devices Market
- Brammer Bio
- Sanofi
- FUJIFILM Diosynth Biotechnologies
- Cell and Gene Therapy Catapult
- Cobra Biologics
- FinVector
- Kaneka Eurogentec S.A.
- MassBiologics
- Spark Therapeutics
- Uniqure
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For